Comparative Study of Antibacterial Effect on Silver Dressing of Negative Pressure Wound
- Conditions
- Diabetes Mellitus
- Registration Number
- NCT02274207
- Lead Sponsor
- Severance Hospital
- Brief Summary
The purpose of this study is to test therapeutic benefits of silver dressing compared with non-silver dressing in NPWT(Negative pressure wound therapy). Silver dressing may antibacterial effect on infected diabetes mellitus foot.
- Detailed Description
Investigator will recruit sixty patients. Participant will be randomly assigned to one of two groups. One is using silver dressing group in NPWT, another is using non-silver dressing group in NPWT. Participant will visit in screening day, NPWT apply day and F/u day for 4 months. Investigators will conduct to check the wound base, Lab, wound culture.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 74
-
The patient above 20 years and has type I, II of diabetes mellitus foot ulcer
-
Infected ulcer has one of below.
-
clinically infection symptom in ulcer area : warmth, erythema, tenderness/swelling
- induration, purulent discharge etc.
-
Confirmed case of bacteria in wound culture.
-
Conformed case of abnormal range of erythrocyte sedimentation rate (ESR)/C-reactive protein(CRP) level in lab.
-
-
Has to be applied NPWT because suture is impossible in ulcer area.
-
The patient voluntary agreed to this protocol.
-
In the opinion of investigator, It is suitable to participate in this study.
-
Infection in bone so patient need amputation
-
Female with childbearing, lactating or not agree to prevent pregnancy.
-
Has Sepsis, Osteomyelitis
-
Has Connective tissue disease of disturbance of healing of wound Ex) Rheumarthritis,systemic lupus erythematosus(SEL), myalgia.
-
The patient to diagnosis of Sickle sell disease or Charcot's joint.
-
The patient stability treated chronic wasting disease.
-
Malignant tumor or history of malignant disease. (Not diagnosis of complete recovery.)
-
The patient treated chemotherapy, radiation therapy, immune-suppressants therapy,adrenocortical hormones therapy.
-
Although necrosis tissue is removed, the target ulcer did not heal because of gangrenous, necrosis tissue or purulent pyorrhea.
-
Has ulcer with cardiac arrhythmia thrombus, venous insufficiency, diabetic necrobiosis lipoidic.
-
In case of using prohibited concomitant medications during study.
a. Oral system steroid b. Immune-suppressive drug c. Unfractionated heparin infusion d. improper drugs in the opinion of investigator.
-
Hypersensitivity with applicators. (NPWT, Silver)
-
The patient participated in other clinical trials within 30 days
-
In the opinion of investigator, the patient is not suitable to participate in this study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Days to patient discharge up to 4 weeks -Examine the days from applied medical device to discharge.
- Secondary Outcome Measures
Name Time Method Number of surgical debridement after NPWT up to 8 weeks -Examine the number of debridement during applied NPWT
Rate of adverse event up to 4 months (if adverse event appeared, Investigator follow until the disappearance of the symptom -Examine adverse event every visit
Complete infection clear rate in wound culture results up to 4 months * Compare screening culture test with every visit culture test
* Examine total complete infection clear rate in each groups. (point to show bacteria minus level in culture test)Days to infection clearance in wound culture results 4 months (at least once a week for 4 weeks / After dischage, every participant visit day(for 3 months)) * Compare screening culture test with every visit culture test
* Examine days to infection clearance(point to show bacteria minus level in culture test)Wound closure rate up to 4 months * Examine total wound closure rate in each groups.
* Wound closure: definition: skin graft, epithelized skin or simple suture et. al.Lab - deviation of level up to 4 months * Compared baseline lab level
* Examine related infection sign level (white blood cell,monocytes,C-reactive protein)
* Finding adverse deviation level through the lab levelDays to complete wound closure 4 months (at least once a week for 4 weeks / After dischage, every participant visit day(for 3 months)) -Examine days from applied medical device to wound closure day
Days of NPWT application period up to 8 weeks -Examine the period of NPWT application
Elevation of wound evaluations grade 4 months (at least once a week for 4 weeks / After dischage, every participant visit day(for 3 months)) * Examine the rate of wound size, wound depth (4 category),granulation tissue grade (5 step),Infection symptom(4 grade)
* Present wound size, infection grade, depth category, granulation tissue grade at every patient visit and examine elevation of wound evaluations compared with baseline.
Trial Locations
- Locations (1)
Severance Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital🇰🇷Seoul, Korea, Republic ofWoojin Choi, MDContact82)2-2228-2195choiwj@yuhs.acHeiji Han, bechelorContact82)2-2228-2195bohemi_han@naver.com